Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changed from v3.8.0 to v3.8.1. The study details remain unchanged.
    Difference
    0.1%
    Check dated 2026-11-18T01:40:06.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov study record for the pembrolizumab and CC-486 ovarian cancer trial is displayed in place of a 403 error page.
    Difference
    61%
    Check dated 2026-11-10T23:19:31.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error instead of study details.
    Difference
    0.2%
    Check dated 2026-11-03T23:00:56.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces an update to terminology used across NIH content. The ClinicalTrials.gov site revision changed from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T22:13:45.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-06T22:37:21.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error page with a minimal header and a Home button. This indicates access restrictions rather than changes to the study content.
    Difference
    0.5%
    Check dated 2026-09-29T22:33:46.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.